Quarterly Result30 Jan 2026, 08:22 pm
Glenmark Pharmaceuticals Reports Q3 FY26 Results: 15.1% YoY Revenue Growth, 15.9% YoY PAT Growth
AI Summary
Glenmark Pharmaceuticals Ltd. announced its financial results for the third quarter ended December 31, 2025. The company reported a 15.1% YoY growth in consolidated revenue, which stood at Rs. 39,006 Mn. EBITDA was Rs. 8,697 Mn, registering 44.9% YoY growth, and Profit After Tax (PAT) was Rs. 4,032 Mn, registering 15.9% YoY growth. The company's performance was driven by strong growth in India, North America, Europe, and Emerging Markets.
Key Highlights
- India Formulations revenue up by 22.1% YoY at Rs. 12,986 Mn
- North America revenue grew by 24.2% YoY to Rs. 9,706 Mn
- Europe revenue grew by 9.1% YoY to Rs.7,963 Mn
- Emerging Markets revenue up by 8.4% YoY to Rs. 8,119 Mn
- Profit After Tax (PAT) of Rs. 4,032 Mn, 15.9% YoY growth